Multicenter Canadian case series of pediatric patients less than 12years of age with moderate‐to‐severe atopic dermatitis treated with dupilumab

Multicenter Canadian case series of pediatric patients less than 12years of age with moderate‐to‐severe atopic dermatitis treated with dupilumab

BackgroundDupilumab is approved for moderate‐severe atopic dermatitis (AD) in patients aged ≥6 months by the US Food and Drug Administration and Health Canada; however, there are little real‐world data because providers have limited practical experience with this recently approved therapy.Objectives...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric dermatology 2024-01, Vol.41 (1), p.5-11
Hauptverfasser: Sylvia Martinez‐Cabriales, Marcoux, Danielle, Carmen Liy‐Wong, Prajapati, Vimal H, Sibbald, Cathryn, Cunningham, Natalie, Lansang, Perla, Tonkin, Rochelle, Joseph, Marissa, Wong, Lauren, Spring, Shanna, Gavigan, Genevieve, Ramien, Michele
Format: Artikel
Sprache:eng
Schlagworte:
Age
Atopic dermatitis
Dermatitis
Dermatology
Eczema
FDA approval
Monoclonal antibodies
Patients
Pediatrics
Pruritus
Quality of life
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BackgroundDupilumab is approved for moderate‐severe atopic dermatitis (AD) in patients aged ≥6 months by the US Food and Drug Administration and Health Canada; however, there are little real‐world data because providers have limited practical experience with this recently approved therapy.ObjectivesTo describe the real‐world effectiveness and safety in patients aged 2 to
ISSN:0736-8046
1525-1470
DOI:10.1111/pde.15418